The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $33.21 down -2.09% from its previous closing price of $33.92. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 0.92 million shares were traded. RNA stock price reached its highest trading level at $34.045 during the session, while it also had its lowest trading level at $33.1.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.
On June 17, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.Wolfe Research initiated its Outperform rating on June 17, 2025, with a $55 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 17 ’25 when Gallagher Kathleen P. sold 911 shares for $30.24 per share. The transaction valued at 27,549 led to the insider holds 50,392 shares of the business.
KATHLEEN GALLAGHER bought 911 shares of RNA for $27,148 on Jun 17 ’25. On Jun 11 ’25, another insider, Flanagan W. Michael, who serves as the Chief Scientific Officer of the company, sold 20,000 shares for $32.88 each. As a result, the insider received 657,694 and left with 80,195 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4002469120 and an Enterprise Value of 2629175808. For the stock, the TTM Price-to-Sale (P/S) ratio is 448.27 while its Price-to-Book (P/B) ratio in mrq is 3.01. Its current Enterprise Value per Revenue stands at 294.52 whereas that against EBITDA is -6.109.
Stock Price History:
The Beta on a monthly basis for RNA is 0.94, which has changed by -0.3101371 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 6.08%, while the 200-Day Moving Average is calculated to be -2.17%.
Shares Statistics:
For the past three months, RNA has traded an average of 1.62M shares per day and 2585680 over the past ten days. A total of 120.51M shares are outstanding, with a floating share count of 109.72M. Insiders hold about 8.98% of the company’s shares, while institutions hold 107.56% stake in the company. Shares short for RNA as of 1751241600 were 16722117 with a Short Ratio of 10.34, compared to 1748563200 on 16174977. Therefore, it implies a Short% of Shares Outstanding of 16722117 and a Short% of Float of 14.000000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
